With leading industrial international service capabilities and in line with international standards, InnoStar provides global pharmaceutical enterprises and research institutions with comprehensive one-stop drug research and development services that meet domestic and international registration standards. By the end of 2022, InnoStar has provided services in more than 1,100 projetcs to more than 600 pharmaceutical companies and new drug research and development institutes in both domestic and abroad, creating a number of "firsts" globally and domestically in innovative drug development services. InnoStar serves a wide range of Class I innovative drugs, covering innovative small molecules, new antibodies (e.g., bispecific/multi-specific antibodies and fusion proteins), ADCs, cell therapy products, gene therapy products and radiopharmaceuticals. In addition, InnoStar has completed research services on several COVID-19 vaccines (mRNA vaccines, recombinant protein vaccines and inactivated vaccines), neutralizing antibodies and small molecules, making great contribution to the prevention and control of COVID-19 in China.